Clinical Report: Correction on Immune Checkpoint Inhibitors with Chemotherapy in Penile SCC
Overview
This correction addresses errors in the author order and institutional affiliation in the original publication on combining neoadjuvant and/or adjuvant immune checkpoint inhibitors with chemotherapy for locally advanced resectable penile squamous cell carcinoma. The scientific content and conclusions of the study remain unchanged.
Background
Locally advanced resectable penile squamous cell carcinoma (SCC) is a challenging malignancy with limited treatment options. Recent approaches have explored combining immune checkpoint inhibitors with chemotherapy in neoadjuvant and adjuvant settings to improve outcomes. Accurate authorship and institutional affiliations are essential for proper attribution and academic integrity in clinical research publications.
Data Highlights
No numerical data or study results were presented in this correction notice; it solely addresses author and affiliation corrections.
Key Findings
The originally published author list contained an incorrect order of the last three authors.
The corrected author list places Qing Yang as the last author, following Bing Ang and Zhigang Zhao.
The institutional affiliation for author group 3 was corrected from the Department of Urology to the Department of Urogenital Cancer at Tianjin Medical University Cancer Institute and Hospital.
The original article has been updated to reflect these corrections.
Clinical Implications
While this correction does not affect clinical data or treatment recommendations, it ensures accurate attribution of contributions and institutional representation. Clinicians referencing the study should cite the corrected author list and affiliations for academic accuracy.
Conclusion
This correction clarifies authorship and affiliation details in the study on immune checkpoint inhibitors combined with chemotherapy for penile SCC, maintaining the integrity of the scientific record without altering clinical findings.
